BlackBarn Capital Partners’s Teva Pharmaceuticals TEVA Stock Holding History

BlackBarn Capital Partners’s Portfolio TEVA Stock Details TEVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-1,000,000	Closed	-$20.2M	–	20
2025 Q3	$20.2M	Sell	1,000,000 -50,000	-5%	-$878K	1.45%	11
2025 Q2	$17.6M	Hold	1,050,000	–	–	1.01%	9
2025 Q1	$16.1M	Hold	1,050,000	–	–	1.03%	11
2024 Q4	$23.1M	Buy	1,050,000 +543,029	+107%	+$9.88M	1.27%	6
2024 Q3	$9.14M	Buy	506,971 +6,971	+1%	+$122K	1.2%	13
2024 Q2	$8.13M	Hold	500,000	–	–	0.72%	17
2024 Q1	$7.05M	Buy	+500,000	New	+$6.3M	3.99%	11

Other funds holding TEVA

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

HIIFS

Harel Insurance Investments & Financial Services Ramat Gan, Israel $20.6B AUM 59.59% 1-Year Est. Return

Phoenix Financial Givatayim, Israel $14.6B AUM 57.48% 1-Year Est. Return

MMH

Menora Mivtachim Holdings Ramat Gan, Israel $25.6B AUM 50.04% 1-Year Est. Return

Clal Insurance Tel-Aviv, Israel $22.3B AUM 79.91% 1-Year Est. Return

MIFH

Migdal Insurance & Financial Holdings Petach Tikva, Israel $15.6B AUM 71.29% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

LIM

Lingotto Investment Management London, United Kingdom $4.67B AUM 70.24% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return

BlackBarn Capital Partners's TEVA Position: Q4 2025 in Review

BlackBarn Capital Partners sold out of Teva Pharmaceuticals (TEVA) in Q4 2025, closing a stake of 1,000,000 shares — an estimated $20.2M sold.

BlackBarn Capital Partners first reported a position in TEVA in Q1 2024 and held it in 7 quarters. The position peaked at $23.1M in Q4 2024. 631 funds tracked by Wall St. Rank hold TEVA as of Q4 2025.

BlackBarn Capital Partners reported no remaining Teva Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
BlackBarn Capital Partners sold 1,000,000 Teva Pharmaceuticals shares in Q4 2025, an estimated $20.2M.
BlackBarn Capital Partners first reported a position in Teva Pharmaceuticals in Q1 2024 and held it in 7 quarters.
BlackBarn Capital Partners's Teva Pharmaceuticals position peaked at $23.1M in Q4 2024.
631 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q4 2025.

Based on BlackBarn Capital Partners's 13F filing for Q4 2025, filed 17 Feb 2026.